<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829933</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-C-J225</org_study_id>
    <nct_id>NCT00829933</nct_id>
  </id_info>
  <brief_title>Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation</brief_title>
  <official_title>A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the incidence of hemorrhagic events in
      patients treated for non-valvular atrial fibrillation with DU-176b at each dose level versus
      warfarin potassium (warfarin). The secondary objective includes between-group comparisons
      with regard to incidence of thromboembolic events, pharmacodynamic parameters, and biomarkers
      for the efficacy evaluation, as well as incidence of adverse events and adverse reaction for
      the safety evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoint was the incidence of bleeding events (major bleeding, clinically relevant non-major bleeding, or minor bleeding) that occurred during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Thromboembolic Events (Cerebral Infarction and Systemic Embolism) Identified During the Period From the Entry to the Treatment Period Until Completion or Termination of the Treatment.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Adverse Reactions Identified During the Period From the Entry to the Treatment Period Until Completion or Termination of the Treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Parameters (PT, PT-INR, and APTT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>PT - prothrombin time INR - International Normalized Ratio APTT - Activated Partial Thromboplastin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma DU-176 Concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarkers (F1+2, TAT, and D-dimer )</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b intermediate dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DU-176b high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b tablets</intervention_name>
    <description>DU-176b tablets taken once daily for up to 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin potassium tablets</intervention_name>
    <description>Warfarin potassium tablets taken once daily for up to 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with non-valvular atrial fibrillation who meet all of the following
             requirements will be considered for admission to the study:

               -  Age≧20years

               -  Atrial fibrillation confirmed by at least 2 electrocardiographic(ECG) tracings
                  taken at an interval of ≧1week during the year before enrollment

          -  Presence of any (at least )one of the following risk factors for embolism:

               -  Hypertension

               -  Diabetes mellitus

               -  Congestive heart failure

               -  Previous transient ischemic attack (TIA) or cerebral infarction (more than 30
                  days before giving informed consent )

               -  Age≧75 years

               -  At time of giving informed consent.

               -  To be confirmed on ECG charts, etc.

        Exclusion Criteria:

          -  Presence of any of the following conditions with increased risk of hemorrhage:

               -  History of intracranial, intraocular (excluding bleeding beneath the bulbar
                  conjunctiva ), intrathecal, retroperitoneal, or non-traumatic intraarticular
                  hemorrhage

               -  History of gastrointestinal hemorrhage during the year before giving informed
                  consent

               -  History of peptic ulcers during the 90 days before giving informed consent

               -  Surgical treatment or trauma requiring hospitalization during the 30 days before
                  giving informed consent

               -  Hemoglobin level &lt;10 g/dL platelet count &lt;10 ×10000 /μL at screening examinations

               -  Active hemorrhage* present at giving informed consent or at enrollment

               -  Any invasive therapeutic or diagnostic procedure (e.g., surgery, tissue, biopsy,
                  and tooth extraction) scheduled during the period from the time of informed
                  consent until completion of the trial treatment.

               -  Any congenital hemorrhagic disease

          -  History of cerebral infarction or TIA within 30 days before giving informed consent

          -  Current treatment with any anticoagulant(other than warfarin)

          -  Concurrent rheumatic valvular disease

          -  History of valvular surgery

          -  Concurrent infectious endocarditis

          -  Concurrent cardiac myxoma

          -  Confirmed left ventricular or left atrial thrombosis

          -  Any congenital condition with a tendency toward thrombosis

          -  Electrical or pharmacological defibrillation scheduled during the trial treatment

          -  Uncontrolled hypertension (persistently high systolic ［&gt;160mmHg］or diastolic
             [&gt;100mmHg] pressure)

          -  Uncontrolled diabetes mellitus

          -  Renal or hepatic dysfunction (as defined below ), confirmed at screening examinations

               -  Serum creatinine&gt;1.5mg/dL

               -  AST(GOT)or ALT(GPT)≧twice the upper limit of the reference range

               -  Total bilirubin ≧twice the upper limit of the reference range

          -  Current antiplatelet therapy for any concomitant illness that may be aggravated after
             discontinuation of the therapy.

          -  Any concurrent severe cardiac disease

          -  Known allergy to warfarin or any condition contraindicating its use

          -  Inability to discontinue current treatment with vitamin K

          -  Confirmed or potential pregnancy, wish to become pregnant during the study period, or
             current breast feeding

          -  Previous treatment with DU-176b

          -  Participation in a trial of any other drug during the 6 month before giving informed
             consent

          -  Any other condition that disqualifies the patient for the study in the opinion of the
             investigator/subinvestigator *This includes ecchymosis identified as at least one
             hematoma sized ≧5 cm in longer diameter, macroscopic hematuria, and microscopic
             hematuria defined as a ≧2+test or a 1+ test for occult blood with a urine sediment
             containing ≧10 red cells per high-power field (except for a 2+ occult blood test
             persisting for 1 year before giving informed consent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>January 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Factor Xa inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DU-176b Low Dose 30mg</title>
          <description>DU-176b tablets:
DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>DU-176b Intermediate Dose 45mg</title>
          <description>DU-176b tablets:
DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>DU-176b High Dose 60mg</title>
          <description>DU-176b tablets:
DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Warfarin</title>
          <description>Warfarin potassium tablets:
Warfarin potassium tablets taken once daily for 12 weeks while adjusting dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline Analysis Population</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="131"/>
                <participants group_id="P4" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrew before treatment started</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis Population is based on Full Analysis Set. FAS defined as all subjects enrolled in study, but excluded those who had GCP violations, who did not receive any dose of study drug, or who did not have atrial fibrillation confirmed by ECG performed at least twice within a 1-week or longer interval within 1 year before registration</population>
      <group_list>
        <group group_id="B1">
          <title>DU-176b Low Dose 30mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>DU-176b Intermediate Dose 45mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>DU-176b High Dose 60mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Warfarin</title>
          <description>Warfarin potassium tablets taken once daily for 12 weeks while adjusting dose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="129"/>
            <count group_id="B5" value="525"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="7.5"/>
                    <measurement group_id="B2" value="69.5" spread="8.8"/>
                    <measurement group_id="B3" value="68.4" spread="8.2"/>
                    <measurement group_id="B4" value="68.8" spread="8.2"/>
                    <measurement group_id="B5" value="69.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.</title>
        <description>The primary endpoint was the incidence of bleeding events (major bleeding, clinically relevant non-major bleeding, or minor bleeding) that occurred during the treatment period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Primary endpoint analyzed for subjects who proceeded to treatment period in FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b Low Dose 30mg</title>
            <description>DU-176b tablets taken once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DU-176b Intermediate Dose 45mg</title>
            <description>DU-176b tablets taken once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>DU-176b High Dose 60mg</title>
            <description>DU-176b tablets taken once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Warfarin</title>
            <description>Warfarin potassium tablets taken once daily for 12 weeks while adjusting dose</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Bleeding Events (Major Bleeding, Clinically Relevant Non-major Bleeding and Minor Bleeding ) Identified During the Period From the Entry Into the Treatment Period Until Completion or Termination of the Treatment.</title>
          <description>The primary endpoint was the incidence of bleeding events (major bleeding, clinically relevant non-major bleeding, or minor bleeding) that occurred during the treatment period.</description>
          <population>Primary endpoint analyzed for subjects who proceeded to treatment period in FAS.</population>
          <units>percent of subjects with bleeding event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="12.7" upper_limit="26.0"/>
                    <measurement group_id="O2" value="22.4" lower_limit="16.2" upper_limit="30.2"/>
                    <measurement group_id="O3" value="27.7" lower_limit="20.7" upper_limit="35.9"/>
                    <measurement group_id="O4" value="20.0" lower_limit="13.9" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the incidence of bleeding events, paired comparison between the DU-176b groups was performed using the χ2 test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.429</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.320</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>18.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Thromboembolic Events (Cerebral Infarction and Systemic Embolism) Identified During the Period From the Entry to the Treatment Period Until Completion or Termination of the Treatment.</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events and Adverse Reactions Identified During the Period From the Entry to the Treatment Period Until Completion or Termination of the Treatment</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Parameters (PT, PT-INR, and APTT)</title>
        <description>PT - prothrombin time INR - International Normalized Ratio APTT - Activated Partial Thromboplastin time</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma DU-176 Concentration</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Biomarkers (F1+2, TAT, and D-dimer )</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DU-176b Low Dose 30mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>DU-176b Intermediate Dose 45mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>DU-176b High Dose 60mg</title>
          <description>DU-176b tablets taken once daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Warfarin</title>
          <description>Warfarin potassium tablets taken once daily for 12 weeks while adjusting dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J V.11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>metastases to spine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA/J V.11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="130"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="134"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="130"/>
                <counts group_id="E4" events="19" subjects_affected="18" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>glucose urine present</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>glood urine present</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="130"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="134"/>
                <counts group_id="E3" events="33" subjects_affected="30" subjects_at_risk="130"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>protein urine present</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="130"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E4" events="16" subjects_affected="6" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>So Yoshino, Manager</name_or_title>
      <organization>Daiichi Sankyo.,LTD</organization>
      <phone>81-90-8024-0742</phone>
      <email>yoshino.so.ej@daiichisankyo.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

